Sign in →

Test Code INHASO Inhibin A, Tumor Marker, Serum

Additional Codes

Mayo Test Code: INHA

Reporting Name

Inhibin A, Tumor Marker, S

Useful For

Aiding in the diagnosis of patients with granulosa cell tumors of the ovary when used in combination with inhibin B

 

Monitoring of patients with granulosa cell tumors and epithelial mucinous-type tumors of the ovary known to secrete inhibin A

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Ordering Guidance


For the initial evaluation of patients suspected of having a granulosa cell tumor of the ovary, order INHAB / Inhibin A and B, Tumor Marker, Serum. If the results of the profile show that either inhibin A or B are elevated, consider monitoring the patient with the individual tests, INHA / Inhibin A, Tumor Marker, Serum or INHB / Inhibin B, Serum.



Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  90 days
  Ambient  7 days

Reference Values

Males: <5.0 pg/mL

 

Females

<11 years: <5.0 pg/mL

11-17 years: <98 pg/mL

Premenopausal: <98 pg/mL

Postmenopausal: <5.0 pg/mL

Day(s) Performed

Monday through Saturday

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86336

LOINC Code Information

Test ID Test Order Name Order LOINC Value
INHA Inhibin A, Tumor Marker, S 23883-2

 

Result ID Test Result Name Result LOINC Value
INHA Inhibin A, Tumor Marker, S 23883-2

Cautions

Inhibin values fluctuate during the menstrual cycle. Inhibin levels in premenopausal women should be interpreted with caution.

 

Do not interpret serum inhibin levels as absolute evidence of the presence or the absence of malignant disease. Use results in conjunction with information from the clinical evaluation of the patient and other diagnostic procedures.

 

Tumor markers are not specific for malignancy and values may vary by testing methodology. The same method should be used to serially monitor patients.

 

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results and the laboratory should be alerted if the result does not correlate with the clinical presentation.

Report Available

1 to 3 days

Specimen Retention Time

3 months

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Method Name

Immunoenzymatic Assay

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.